11/20
08:06 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/20
08:01 am
cldx
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Medium
Report
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
11/11
04:01 pm
cldx
Celldex Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Celldex Therapeutics to Present at Upcoming Investor Conferences
11/8
05:43 am
cldx
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/7
04:11 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/6
07:28 pm
cldx
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
04:22 pm
cldx
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/6
04:01 pm
cldx
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/28
01:16 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/28
07:13 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years [Yahoo! Finance]
Low
Report
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years [Yahoo! Finance]
10/26
05:49 pm
cldx
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria [Yahoo! Finance]
Low
Report
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria [Yahoo! Finance]
10/26
05:43 pm
cldx
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Low
Report
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
10/25
08:10 am
cldx
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 [Yahoo! Finance]
High
Report
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 [Yahoo! Finance]
10/25
08:01 am
cldx
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Medium
Report
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
10/15
06:16 pm
cldx
Celldex Therapeutics, Inc. (CLDX): Hedge Funds' Hidden Gem in Small-Cap Stocks [Yahoo! Finance]
Low
Report
Celldex Therapeutics, Inc. (CLDX): Hedge Funds' Hidden Gem in Small-Cap Stocks [Yahoo! Finance]
10/7
08:10 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $70.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $70.00 price target on the stock.
9/30
07:46 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $45.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $45.00 price target on the stock.
9/27
07:41 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
9/27
07:35 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.
9/26
08:17 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
High
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/25
12:21 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
High
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
9/25
10:50 am
cldx
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 [Yahoo! Finance]
Low
Report
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 [Yahoo! Finance]
9/25
10:45 am
cldx
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
High
Report
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
9/16
12:11 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
9/16
08:09 am
cldx
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 [Yahoo! Finance]
Medium
Report
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 [Yahoo! Finance]